Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
free free
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve Pubget Overpricing |
lüll Critical molecular pathways in cancer stem cells of chronic myeloid leukemia Chen Y; Peng C; Sullivan C; Li D; Li SLeukemia 2010[Sep]; 24 (9): 1545-54Inhibition of BCR-ABL with kinase inhibitors in the treatment of Philadelphia-positive (Ph(+)) chronic myeloid leukemia (CML) is highly effective in controlling but not curing the disease. This is largely due to the inability of these kinase inhibitors to kill leukemia stem cells (LSCs) responsible for disease relapse. This stem cell resistance is not associated with the BCR-ABL kinase domain mutations resistant to kinase inhibitors. Development of curative therapies for CML requires the identification of crucial molecular pathways responsible for the survival and self-renewal of LSCs. In this review, we will discuss our current understanding of these crucial molecular pathways in LSCs and the available therapeutic strategies for targeting these stem cells in CML.|*Neoplastic Stem Cells[MESH]|Animals[MESH]|Antineoplastic Agents/therapeutic use[MESH]|Disease Models, Animal[MESH]|Genes, abl[MESH]|Humans[MESH]|Leukemia, Myelogenous, Chronic, BCR-ABL Positive/drug therapy/*pathology[MESH]|Mice[MESH]|Mice, Transgenic[MESH]|Mutation[MESH]|Protein Kinase Inhibitors/therapeutic use[MESH] |